Levicept Ltd

Levicept Ltd is a UK-based biotechnology company developing the first in a new class of novel, safe and efficacious biological therapies, LEVI-04 [p75NTR-Fc], for the treatment of osteoarthritis and chronic pain. LEVI-04 inhibits NT-3, one of the neurotrophin family of proteins. LEVI-04 has completed a Phase II clinical trial in more than 500 patients with osteoarthritis. It is estimated that the market opportunity for drugs that treat osteoarthritis is worth in excess of $10 billion. LEVI-04 was discovered by Levicept’s founder, Simon Westbrook. Levicept’s investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures.

https://levicept.com/ 2 press releases

Press Releases from Levicept Ltd

Displaying 2 press releases

July 7, 2026

Levicept Appoints Darlene Deptula-Hicks as CFO

H ighly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Sandwich, UK – 7th July 2026 – Levicept Ltd, a biotechnology company focused on the development of LEVI-04, ...

Read Full Release →

March 30, 2026

Levicept Announces The Lancet Publication of LEVI-04 Phase II Clinical Trial Results, Showing Significant Reduction in Pain and Symptoms of Osteoarthritis

Significant improvements in pain, function and patient global outcomes demonstrated LEVI-04 well tolerated and exhibits a favourable safety profile Sandwich, UK – 30 March 2026 – Levicept Ltd, a biotechnology company focused on the development of ...

Read Full Release →